Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it has completed patient enrolment for the Phase IIa clinical trial for its drug candidate QGC001.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2016/01/QGC_PR_QGC001-Recrutement-100pct-patients_05012016_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
